NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
REDDenosumab 120mg XGEVA®
(Injection) 		Endocrine system, Denosumab, 06.06.02
Amber SPADenosumab 60mg/1mL Prolia®
(Injection, pre-filled syringe) 		Endocrine system, Denosumab, 06.06.02
Links found
MHRA Drug Safety Update (July 2015) - Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk
MHRA Drug Safety Update (July 2015) - Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk
MHRA Drug Safety Update (May 2022): Denosumab 60mg (Prolia): should not be used in patients under 18 years due to the risk of serious hypercalcaemia
MHRA Drug Safety Update June 2017: Denosumab (Prolia, Xgeva▼): reports of osteonecrosis of the external auditory canal
MHRA Drug Safety Update: Denosumab 60mg (Prolia): increased risk of multiple vertebral fractures after stopping or delaying ongoing treatment (August 2020)
MHRA DSU (June 18): Denosumab (Xgeva▼) for advanced malignancies involving bone: study data show new primary malignancies reported more frequently compared to zoledronate
MHRA DSU (June 18): Denosumab (Xgeva▼) for giant cell tumour of bone: risk of clinically significant hypercalcaemia following discontinuation
MHRA DSU June 2017: Denosumab (Prolia, Xgeva▼): reports of osteonecrosis of the external auditory canal
NICE TA204: Osteoporotic fractures - denosumab